Roddie et al. presented at 2020 ASH annual meeting results of 19 R/R B-ALL patients with a median age of 43 years (range 18–62), who received a novel CD19 CAR (CAT-41BBz CAR) (Phase I ALLCAR19-NCT02935257—a study of AUTO1) [53]. Here, CD19 is linked to acute lymphoblastic leukemia.